Tens of thousands of high-risk Israelis can now get an antibody treatment as hospital outpatients as soon as they are diagnosed with COVID-19, in the hope that it will prevent deterioration to serious illness.

The Health Ministry has a supply of  thousands of doses of the US-made Bamlanivimab, which is intended specifically for non-serious patients. It has started distributing them to doctors, who are now offering the two-hour infusion-based treatment to outpatients in certain high-risk categories who test positive for the virus.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

Jerusalem’s Hadassah Medical Center became the first institution to start giving the treatment on Monday, administering it to four outpatients, and other hospitals are expected to follow.

Bamlanivimab is composed of monoclonal antibodies, which are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens including viruses.

Read more at Times of Israel.